MDL | - |
---|---|
Molecular Weight | 369.50 |
Molecular Formula | C23H31NO3 |
SMILES | C#C[C@@]1(OC(C)=O)CC[C@@]2([H])[C@]3([H])CCC4=C/C(CC[C@]4([H])[C@@]3([H])CC[C@]12CC)=N/O |
Norgestimate is converted to at least two active metabolites: levonorgestrel 3-oxime (deacetylated norgestimate; norelgestromin) and levonorgestrel [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT04828824 | University of Colorado, Denver |
Contraception Behavior
|
June 18, 2021 | Phase 4 |
NCT00554632 | University of Vermont|University of Vermont Medical Center |
Venous Thrombosis
|
April 2003 | Not Applicable |
NCT02127593 | Janssen Research & Development, LLC |
Healthy
|
June 2013 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
DMSO : 125 mg/mL ( 338.29 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.7064 mL | 13.5318 mL | 27.0636 mL |
5 mM | 0.5413 mL | 2.7064 mL | 5.4127 mL |
10 mM | 0.2706 mL | 1.3532 mL | 2.7064 mL |